Skip to content
lifestyle.brickvest.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
AB Science
AB Science is invited to present at the 2026 ENCALS annual meeting the survival data from masitinib clinical program in ALS
June 9, 2026
AB Science : Stonegate Capital Partners updates its coverage of AB Science’s stock with a target price of EUR 4.25 per share
June 2, 2026
AB Science announces that its stock continues to be covered by Maxim Group, with a target price of €4.00 per share
May 27, 2026
AB Science reports its revenues for the year 2025 and provides an update on its activities
May 25, 2026
AB Science announces a final agreement on the renegotiation of the repayment terms of its loans with all of its financial creditors
May 23, 2026
AB Science: New publication on medrxiv demonstrating substantial survival benefits and preserved quality of life with masitinib in ALS patients
May 22, 2026
AB Science provides an update on its clinical development program.
May 22, 2026
AB Science reçoit un avis d’autorisation pour un brevet américain couvrant le masitinib dans le traitement du cancer de la prostate métastatique hormono-resistant
January 29, 2026
AB Science obtient un brevet japonais pour l’utilisation du masitinib dans le traitement des formes progressives de la sclérose en plaques (SEP) jusqu’en 2041
January 21, 2026